Verona Pharma PLC VRNA
We take great care to ensure that the data presented and summarized in this overview for Verona Pharma plc is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding VRNA
View all-
Perceptive Advisors LLC New York, NY6.39MShares$419 Million9.9% of portfolio
-
Nea Management Company, LLC Timonium, MD5.58MShares$366 Million18.53% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA3.38MShares$222 Million9.42% of portfolio
-
Eventide Asset Management, LLC Boston, MA3.13MShares$205 Million2.79% of portfolio
-
Lee Ainslie Maverick Capital LTD | Dallas, Tx3.13MShares$205 Million2.81% of portfolio
-
Wellington Management Group LLP Boston, MA3.03MShares$198 Million0.03% of portfolio
-
Abingworth LLP London, X02.46MShares$161 Million21.3% of portfolio
-
Vivo Capital, LLC Palo Alto, CA2.28MShares$150 Million20.7% of portfolio
-
Summit Partners Public Asset Management, LLC Boston, MA1.9MShares$125 Million2.14% of portfolio
-
Jennison Associates LLC1.89MShares$124 Million0.05% of portfolio
Latest Institutional Activity in VRNA
Top Purchases
Top Sells
About VRNA
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.
Insider Transactions at VRNA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 03
2025
|
Kathleen A. Rickard Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
33,240
-1.22%
|
$232,680
$7.16 P/Share
|
|
Feb 03
2025
|
Mark W Hahn Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
166,888
-1.24%
|
$1,168,216
$7.16 P/Share
|
|
Feb 03
2025
|
David Zaccardelli President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
166,728
-1.16%
|
$1,167,096
$7.16 P/Share
|
|
Feb 01
2025
|
Kathleen A. Rickard Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+1.8%
|
-
|
|
Feb 01
2025
|
Mark W Hahn Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
200,000
+1.46%
|
-
|
|
Feb 01
2025
|
David Zaccardelli President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
200,000
+1.37%
|
-
|
|
Dec 06
2024
|
Mark W Hahn Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
183,728
-1.36%
|
$918,640
$5.01 P/Share
|
|
Dec 06
2024
|
David Zaccardelli President and CEO |
SELL
Open market or private sale
|
Direct |
162,800
-1.13%
|
$814,000
$5.01 P/Share
|
|
Dec 05
2024
|
Mark W Hahn Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
640,048
-4.53%
|
$3,200,240
$5.01 P/Share
|
|
Dec 05
2024
|
David Zaccardelli President and CEO |
SELL
Open market or private sale
|
Direct |
640,264
-4.27%
|
$3,201,320
$5.01 P/Share
|
|
Dec 04
2024
|
Mark W Hahn Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
58,184
-0.41%
|
$290,920
$5.0 P/Share
|
|
Dec 04
2024
|
David Zaccardelli President and CEO |
SELL
Open market or private sale
|
Direct |
67,608
-0.45%
|
$338,040
$5.0 P/Share
|
|
Dec 02
2024
|
Mark W Hahn Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,600
-0.01%
|
$8,000
$5.0 P/Share
|
|
Dec 02
2024
|
David Zaccardelli President and CEO |
SELL
Open market or private sale
|
Direct |
3,200
-0.02%
|
$16,000
$5.0 P/Share
|
|
Nov 29
2024
|
Mark W Hahn Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
98,704
-0.69%
|
$493,520
$5.01 P/Share
|
|
Nov 29
2024
|
David Zaccardelli President and CEO |
SELL
Open market or private sale
|
Direct |
98,888
-0.65%
|
$494,440
$5.01 P/Share
|
|
Nov 27
2024
|
Mark W Hahn Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
12,936
-0.09%
|
$64,680
$5.0 P/Share
|
|
Nov 27
2024
|
David Zaccardelli President and CEO |
SELL
Open market or private sale
|
Direct |
23,240
-0.15%
|
$116,200
$5.0 P/Share
|
|
Nov 26
2024
|
Mark W Hahn Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
800
-0.01%
|
$4,000
$5.0 P/Share
|
|
Nov 25
2024
|
David Zaccardelli President and CEO |
SELL
Open market or private sale
|
Direct |
1,600
-0.01%
|
$8,000
$5.0 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 137K shares |
|---|---|
| Grant, award, or other acquisition | 4.9M shares |
| Payment of exercise price or tax liability | 2.18M shares |
|---|---|
| Open market or private sale | 5.88M shares |